Accounting for the increase in NSAID expenditure: substitution or leakage?

BACKGROUND: National Institute of Health and Clinical Excellence (NICE) guidance stated that a new form of non-steroidal anti-inflammatory drug (NSAID) (selective COX-2 inhibitors) should only be an option for arthritis patients at high risk of a gastro-intestinal (GI) event. Total expenditure on NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Barton, Garry R, Avery, Anthony J, Whynes, David K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1501056/
https://www.ncbi.nlm.nih.gov/pubmed/16737538
http://dx.doi.org/10.1186/1478-7547-4-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1501056/
https://www.ncbi.nlm.nih.gov/pubmed/16737538
http://dx.doi.org/10.1186/1478-7547-4-9

Ejemplares similares